Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases

Journal of Parenteral and Enteral Nutrition

Volumn 38, Issue 3, 2014, Pages 385-391

  Zator, Zachary A ^a   Cantu, Stephanie M ^a   Konijeti, Gauree Gupta ^a   Nguyen, Deanna D ^a   Sauk, Jenny ^a   Yajnik, Vijay ^a   Ananthakrishnan, Ashwin N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biologic therapy; Crohn's disease; ulcerative colitis; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID DERIVATIVE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG EFFECT; DRUG EXPOSURE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCERATIVE COLITIS; VITAMIN BLOOD LEVEL; YOUNG ADULT;

BIOLOGIC THERAPY; CROHN'S DISEASE; ULCERATIVE COLITIS; VITAMIN D;

ADOLESCENT; ADULT; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84895729961     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607113504002     Document Type: Article

References (32)

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 ; 357: 266-281
2. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004 ; 80: 1678S - 1688S
3. Cantorna MT, Mahon BD. D-hormone and the immune system. J Rheumatol Suppl. 2005 ; 76: 11-20 (Pubitemid 41324839)
4. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004 ; 229: 1136-1142 (Pubitemid 39602256)
5. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004 ; 80: 1717S - 1720S
6. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011 ; 35: 308-316
7. Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008 ; 103: 1451-1459 (Pubitemid 351813899)
8. Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol. 2004 ; 39: 527-533 (Pubitemid 38996894)
9. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology. 2012 ; 142: 482-489
10. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012 ; 380: 1590-1605
11. Bernstein CN, Loftus EV, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn's disease. Gut. 2012 ; 61: 622-629
12. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol. 2011 ; 106: 199-213
13. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012 ; 380: 1606-1619
14. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011 ; 33: 987-995
15. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxy- cholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000 ; 130: 2648-2652
16. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007 ; 8: 5
17. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003 ; 17: 2386-2392 (Pubitemid 37542204)
18. Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology. 2006 ; 117: 310-318
19. Garg M, Lubel JS, Sparrow MP, Holt SG, Gibson PR. Review article: vitamin D and inflammatory bowel disease - established concepts and future directions. Aliment Pharmacol Ther. 2012 ; 36: 324-344
20. Narula N, Marshall JK. Management of inflammatory bowel disease with vitamin D: beyond bone health. J Crohns Colitis. 2012 ; 6: 397-404
21. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005 ; 2: 308-315 (Pubitemid 41102862)
22. Nicholson I, Dalzell AM, El-Matary W. Vitamin D as a therapy for colitis: a systematic review. J Crohns Colitis. 2012 ; 6: 405-411
23. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis. 2013 ; 19: 1921-1927
24. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010 ; 32: 377-383
25. Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005 ; 35: 217-224 (Pubitemid 40123868)
26. de Silva PS, Nguyen DD, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan AN. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012 ; 36: 459-466
27. Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 ; 19: 309-315
28. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006 ; 55: 749-753 (Pubitemid 43764536)
29. Joseph AJ, George B, Pulimood AB, Seshadri MS, Chacko A. 25 (OH) vitamin D level in Crohn's disease: association with sun exposure & disease activity. Indian J Med Res. 2009 ; 130: 133-137
30. Neve A, Corrado A, Cantatore FP. Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clin Exp Med. :
31. Stio M, Treves C, Martinesi M, d'Albasio G, Bagnoli S, Bonanomi AG. Effect of anti-TNF therapy and vitamin D derivatives on the proliferation of peripheral blood mononuclear cells in Crohn's disease. Dig Dis Sci. 2004 ; 49: 328-335 (Pubitemid 38392239)
32. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis. 2009 ; 15: 1656-1662